Cerebrolysin
Cerebrolysin is a porcine brain-derived mixture of low-molecular-weight peptides and free amino acids rather than one molecular entity.
The short version
- Why people discuss it
- Discussed for cognitive support and neurological recovery after injury or illness. Community interest does not establish benefit or a suitable treatment.
- What it is
- Cerebrolysin is a porcine brain-derived mixture of low-molecular-weight peptides and free amino acids rather than one molecular entity.
- Biggest caution
- Evidence for a defined infusion product cannot be transferred to oral, nasal or unverified preparations. Mixture composition, clinical setting and study quality must remain visible.
- Stack context
- Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Sources report different amounts or schedules; the reference below is a named example, not a consensus.
Named Cerebrolysin solution — intramuscular
Community reference · Not clinical guidance- Amount
- 1–5 mL
- Frequency
- Once daily
- Duration / phase
- 20–30 days
Legacy regional-product/community context expressed in mL. A newer lyophilized-product protocol uses mg and subcutaneous dosing; it is not an equivalent preparation or a substitute for the named solution. Reference only; this does not establish safety, effectiveness or individual suitability.
Reference source · reviewed 2026-09-12Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
20→32 mg SC daily from a lyophilized vial, 8–12 weeks; overview describes commercial solution in mL by IM/IV routes.
Evidence & sources · Community source profile
AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.
- AxonRep community research synthesisAxonRep synthesis · Checked 2026-09-12
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27